Pay in 4 interest-free payments of $6.31 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
In Phase 3 studies: Participants without diabetes taking orforglipron lost approximately 9% to 10% of body weight over roughly 36 to 40 weeks Participants with type 2 diabetes generally lost around 7% to 8% By comparison, Wegovy's landmark STEP trials reported approximately 14.9% average weight loss over 68 weeks
Oral GLP-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now
Clinical trial data shows that lean mass loss occurs in most participants on semaglutide and tirzepatide, with estimates ranging from 25% to 40% of total weight lost
A lab test can show if you are low
US$ 21.51
US$ 29.89
US$ 29.82
US$ 24.97
US$ 27.22
US$ 28.35
US$ 29.76
US$ 25.48
